PET has been previously reported as an unreliable biomarker [23], whereas dopamine transporter SPECT imaging, in combination with olfactometry, is currently being used in an ongoing prospective study of PD pathogenesis [13]. This evidence concerns the gene SLC6A3 and Parkinson disease.